Media coverage
2Media coverage
Title U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the Media name/outlet PR Newswire Country United States Date 10/30/18 Persons Ralph A Defronzo Title U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the Media name/outlet PR Newswire Country United States Date 10/30/18 Persons Ralph A Defronzo